Мероприятия

 

Ингибиторы протонной помпы с позиции эффективности и безопасности
Автор: Н. Захарова   

 

magazine-vrach-2013-10-003

Ингибиторы протонной помпы с позиции эффективности и безопасности

Ингибиторы протонной помпы (ИПП), или ингибиторы H + , К + -аденозинтрифосфатазы (АТФазы), – самый часто назначаемый класс препаратов для лечения кислотозависимых заболеваний. В статье раскрываются механизмы действия ИПП, рассматриваются фармакокинетические особенности препаратов этой группы, новые специфические побочные реакции.
Proton pump inhibitors in the context of their efficacy and safety
Proton pump inhibitors (PPI), or H + , K + -ATPase inhibitors, are the most commonly prescribed class of drugs to treat acid-dependent diseases. The paper unveils the mechanisms of action of PPI and considers the pharmacokinetic properties of drugs from this group and novel specific adverse reactions.Proton pump inhibitors (PPI), or H + , K + -ATPase inhibitors, are the most commonly prescribed class of drugs to treat acid-dependent diseases. The paper unveils the mechanisms of action of PPI and considers the pharmacokinetic properties of drugs from this group and novel specific adverse reactions.

 

Литература
1. Barkun A., Bardou M., Pham C. et al. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis // Am. J. Gastroenterol. – 2012; 107 (4): 507–20.
2. Blume H. et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors // Drug. Safety. – 2006; 29 (9): 769–84.
3. Bavishi C., Dupont H. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection // Aliment. Pharmacol. Ther. – 2011; 34 (11–12): 1269–81.
4. Cohen J. Switching omeprazole in Sweden and the United States // Am. J. Ther. – 2003; 10 (5): 370–6.
5. Epstein M., McGrath S., Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism // N. Engl. J. Med. – 2006; 355 (17): 1834–6.
6. Filion K. еt al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis // Gut, 2013.
7. Gerson L. et al. Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature // Dig. Dis. Sci. – 2012; 57 (5): 1304–13.
8. Fendrick A., Shaw M., Schachtel B. et al. Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn // Clin. Gastroenterol. Hepatol. – 2004; 2 (1): 17–21.
9. Ito T., Jensen R. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium // Cur. Gastroenterol. Rep. – 2010; 12 (6): 448–57.
10. Jianu C. et al. Gastric carcinoids after long-term use of a proton pump inhibitor // Aliment. Pharmacol. Ther. – 2012; 36 (7): 644–9.
11. Kreutz R., Stanek E., Aubert R. et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study // Pharmacotherapy. – 2010; 30 (8): 787–96.
12. Labenz J., Petersen K., Rösch W. et al. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole // Aliment. Pharmacol. Ther. – 2003; 17 (8): 1015–9.
13. Li H., Meng L., Liu F. et al. H+/K+-ATPase inhibitors: a patent review // Exp. Opin. Ther. Pat. – 2013; 23 (1): 99–111.
14. Li X., Andersson T., Ahlström M. et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities // Drug. Metab. Dispos. – 2004; 32 (8): 821–7.
15. Malfertheiner P. et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. European Helicobacter Study Group // Gut. – 2012; 61 (5): 646–64.
16. Modlin I., Sachs G. Acid related diseases. Biology and treatment / Schnetztor-Verlag GmbH Konstanz, 1998; 368 p.
17. Nederlands Bijwerkingen Centrum Lareb, Mei 2007 http://www.lareb.nl/documents/kwb_2006_4_omep.pdf
18. Nexium® (esomeprazole magnesium). Description. NDA 21-153/S-008. http://www.fda.gov.
19. Pauli-Magnus C., Rekersbrink S., Klotz U. et al. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein // Naunyn Schniedebergs Arch. Pharmacol. – 2001; 364: 551–7.
20. Puig I. et al. Meta-analysis: comparative efficacy of H2-receptor antagonists and proton pump inhibitors for reducing aspiration risk during anaesthesia depending on the administration route and schedule // Pharmacol. Res. – 2012; 65 (4): 480–90.
21. Shin J., Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors // J. Neurogastroenterol. Motil. – 2013; 19 (1): 25–35.
22. Tamura T. et al. Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System // Int. J. Med. Sci. – 2012; 9 (5): 322–6.
23. Horai Y., Kimura M., Furuie H. et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes // Aliment. Pharmacol. Ther. – 2001; 15 (6): 805–12.
24. WHO Pharmaceuticals Newsletter No.1.2005.3 http://www.who.int/medicines/publications/newsletter
25. WHO Pharmaceuticals Newsletter No.1.2006.7 http://www.who.int/medicines/publications/newsletter
26. Yu E., Bauer S., Bain P., Bauer D. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies // Am. J. Med. – 2011; 124 (6): 519–26.
 

 
Рассылка
Важно

→ Фармакопейные статьи


→ Медицинские архивы на службе современного врача


→ Перечень медицинских технологий

ЭКД архив

 

Баннер
Баннер
Баннер
Информационные партнеры:
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер
Баннер